Anavex Life Sciences Corp (AVXL)

[CogDiss 1188X]

Analyst in earnings call let slip the following:

Tom Bishop
But is there some reason for the acceleration? (Increasing the number pad trial sites in the AD trial) I must admit to having had some exciting anecdotal news of patient improvements coming out of Australia.

This may be one of the reasons the stock price has started to move recently. The old $300 million market cap “rule” (if there is such a thing) before results are announced may be coming into play.